# US 2020/0368213 A1 · Methods of treating hepatic encephalopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368213 A1
- Document ID: US20200368213A1
- Status: Published application
- Kind: A1
- Application number: 16/893,651
- Filed: 2020-06-05
- Published: 2020-11-26
- Earliest claimed: 2008-10-02
- Assignees: Salix Pharmaceuticals, Inc.
- Applicants: Salix Pharmaceuticals, Inc.
- Inventors: William Forbes
- Web page: https://patentgrep.com/patent/US20200368213A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/4164: 1,3-Diazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/606: having amino groups
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 31/785: Polymers containing nitrogen
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 38/31: Somatostatins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

A method of decreasing a subject's risk of a hepatic encephalopathy (HE) breakthrough episode comprising administering rifaximin to a subject suffering from HE.

### Claim 4 (depends on 3)

The method of claim 3, wherein the risk of the episode for subjects having a last HE episode equal to, or greater than, 90 days prior to the administration is reduced by about 58% or between about 30% to 70% or between about 40% to about 70%.

### Claim 5

(canceled)

### Claim 6 (depends on 3)

The method of claim 3, wherein the risk of the episode for subjects having a last HE episode greater than 90 days prior to the administration is decreased by between about 60% or between about 2% to 80%.

### Claim 7

(canceled)

### Claim 8 (depends on 3)

The method of claim 3, wherein the risk of the episode for subjects having two or fewer HE episodes in the six months prior to the administration is reduced by about 56% or between about 20% to 70%.

### Claim 9

(canceled)

### Claim 10 (depends on 3)

The method of claim 3, wherein the risk of the episode for subjects having greater than two HE episodes in the six months prior to rifaximin administration is reduced by about 63% or between about 30% to about 80%.

### Claim at position 11

11-13. (canceled)

### Claim 14

A method of maintaining remission of HE in a subject comprising administering rifaximin to a subject suffering from HE.

### Claim 15

A method of reducing the frequency of hospitalization visits by an HE patient, comprising administering rifaximin to a subject suffering from HE.

### Claim 16 (depends on 15)

The method of claim 15, wherein administration of rifaximin reduces hospitalization frequency by about 48% or from between about 13% to about 69%.

### Claim at position 15

17-19. (canceled)

### Claim 20 (depends on 15)

The method of claim 15[[19]], wherein 550 mg of rifaximin is administered to the subject two times per day (BID) or 275 mg of rifaximin is administered to the subject four times per day or 275 mg of rifaximin is administered to the subject as two dosage forms two times per day.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 3)

The method of claim 3, wherein the GI specific antibiotic is administered to the subject for six months, one year, two to three years, or until the subject's death.

### Claim at position 20

24-26. (canceled)

### Claim 27 (depends on 3)

The method of claim 3, wherein a Conn score or the quality of life (QoL) measurement of the subject is improved over baseline following administration of rifaximin.

### Claim 28

(canceled)

### Claim 29 (depends on 3)

The method of claim 3, further comprising administering one or more of align, alinia, lactulose, pentasa, cholestyramine, sandostatin, vancomycin, lactose, amitiza, flagyl, zegerid, prevacid, or miralax.

### Claim at position 24

30-37. (canceled)

### Claim 38 (depends on 3)

The method of claim 3, wherein there is an increase in time to a first HE-related hospitalization of the subject, an increase in the time to development of spontaneous bacterial peritonitis (SBP) of the subject or an increase in critical flicker frequency values from baseline after administration of rifaximin to the subject.

### Claim 39

(canceled)

### Claim 40 (depends on 3)

The method of claim 3, wherein there is a decrease in blood ammonia concentration from baseline or a decrease in daily lactulose consumption from baseline over time after administration of rifaximin to the subject.

### Claim at position 28

41-46. (canceled)

### Claim 47 (depends on 3)

The method of claim 3, wherein there is a shift in baseline in Conn scores, in asterixis grades, in Chronic Liver Disease Questionnaire (CLDQ) scores or in Epworth Sleepiness Scale scores over time after administration of rifaximin to the subject.

### Claim at position 30

48-51. (canceled)

### Claim 52 (depends on 3)

The method of claim 3, wherein subjects having a meld level of between about 1 to 24 respond to treatment with rifaximin.

### Claim at position 32

53-74. (canceled)

### Claim 75

A method of increasing the time between breakthrough events for a patient suffering from hepatic encephalopathy, comprising administering to the patient an effective amount of rifaximin that extends the time between hepatic encephalopathy breakthrough events.

### Claim 76 (depends on 75)

The method of claim 75, wherein the time between breakthrough events for the patient is extended to greater than six months or greater than 12 months.

### Claim at position 35

77-96. (canceled)
